811 results on '"Cheng, Seng"'
Search Results
152. Gene therapy for the neurological manifestations in lysosomal storage disorders
153. Nanometric material removal using the electrokinetic phenomenon
154. Maskless lithography using off-the-shelf inkjet printer
155. Crystallization and X-ray crystallographic analysis of recombinant TylP, a putative γ-butyrolactone receptor protein from Streptomyces fradiae.
156. Formulation of Synthetic Vectors for Cystic Fibrosis Gene Therapy
157. Formulation of Synthetic Gene Delivery Vectors for Transduction of the Airway Epithelium
158. GBA2-Encoded β-Glucosidase Activity Is Involved in the Inflammatory Response to Pseudomonas aeruginosa
159. Systemic Administration of a Recombinant AAV1 Vector Encoding IGF-1 Improves Disease Manifestations in SMA Mice
160. Translational Fidelity of Intrathecal Delivery of Self-Complementary AAV9–Survival Motor Neuron 1 for Spinal Muscular Atrophy
161. Silencing Mutant Huntingtin by Adeno-Associated Virus-Mediated RNA Interference Ameliorates Disease Manifestations in the YAC128 Mouse Model of Huntington's Disease
162. Antisense Oligonucleotide-mediated Suppression of Muscle Glycogen Synthase 1 Synthesis as an Approach for Substrate Reduction Therapy of Pompe Disease
163. Reversibility of neuropathology in Tay–Sachs-related diseases
164. Design of a dynamic fuzzy controller IC with application to garage parking control
165. Erythrocytes encapsulated with phenylalanine hydroxylase exhibit improved pharmacokinetics and lowered plasma phenylalanine levels in normal mice
166. Therapeutic Response in Feline Sandhoff Disease Despite Immunity to Intracranial Gene Therapy
167. A Bispecific Protein Capable of Engaging CTLA-4 and MHCII Protects Non-Obese Diabetic Mice from Autoimmune Diabetes
168. Systemic Delivery of a Peptide-Linked Morpholino Oligonucleotide Neutralizes Mutant RNA Toxicity in a Mouse Model of Myotonic Dystrophy
169. Dysregulation of Multiple Facets of Glycogen Metabolism in a Murine Model of Pompe Disease
170. Augmenting glucocerebrosidase activity in the CNS as a therapeutic strategy for Gaucher-related synucleinopathies
171. A novel, selective and orally-available glucosylceramide synthase inhibitor for substrate reduction therapy of Fabry disease
172. Antisense Oligonucleotide-Mediated Correction of Transcriptional Dysregulation is Correlated with Behavioral Benefits in the YAC128 Mouse Model of Huntington's Disease
173. Fibrillin-1 Regulates Skeletal Stem Cell Differentiation by Modulating TGFβ Activity Within the Marrow Niche.
174. Analytical performance monitoring of a 142.5kWp grid-connected rooftop BIPV system in Singapore
175. Gene Transfer to the CNS Is Efficacious in Immune-primed Mice Harboring Physiologically Relevant Titers of Anti-AAV Antibodies
176. Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease
177. Gene Transfer Corrects Acute GM2 Gangliosidosis—Potential Therapeutic Contribution of Perivascular Enzyme Flow
178. Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis
179. Ligation of CTLA-4 to the TCR inhibits T cell activation and directs differentiation into Foxp3+ regulatory T cells (72.2)
180. Proteasome Inhibition Is Partially Effective in Attenuating Pre-Existing Immunity against Recombinant Adeno-Associated Viral Vectors
181. Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann–Pick C mice
182. Ligation of Cytotoxic T Lymphocyte Antigen-4 to T Cell Receptor Inhibits T Cell Activation and Directs Differentiation into Foxp3+ Regulatory T Cells
183. Glucosylceramide Synthase Inhibition Reduces Gb3 and Lyso-Gb3 in a Mouse Model Of Fabry Disease
184. Chemical Composition and Antitermitic Activity against Coptotermes formosanusShiraki of Cryptomeria japonica Leaf Essential Oil
185. Mutant GBA1 Expression and Synucleinopathy Risk: First Insights from Cellular and Mouse Models
186. Systemic Administration of AAV8-α-galactosidase A Induces Humoral Tolerance in Nonhuman Primates Despite Low Hepatic Expression
187. Disease progression in a mouse model of amyotrophic lateral sclerosis: the influence of chronic stress and corticosterone
188. Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system
189. Iminosugar-Based Inhibitors of Glucosylceramide Synthase Increase Brain Glycosphingolipids and Survival in a Mouse Model of Sandhoff Disease
190. Phylogenetic Relationships of the Genus Chamaecyparis Inferred from Leaf Essential Oil
191. Lowering Glycosphingolipid Levels in CD4+ T Cells Attenuates T Cell Receptor Signaling, Cytokine Production, and Differentiation to the Th17 Lineage
192. Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy
193. Basis for the relationship between Gaucher disease and synucleinopathies
194. Inhibiting glycogen biosynthesis by mTORC1 suppression as an adjunct therapy for Pompe disease
195. Comparative Analysis of Acid Sphingomyelinase Distribution in the CNS of Rats and Mice Following Intracerebroventricular Delivery
196. Induction of Immune Tolerance to a Therapeutic Protein by Intrathymic Gene Delivery
197. AAV4-mediated Expression of IGF-1 and VEGF Within Cellular Components of the Ventricular System Improves Survival Outcome in Familial ALS Mice
198. Substrate Reduction Augments the Efficacy of Enzyme Therapy in a Mouse Model of Fabry Disease
199. Preexisting Immunity and Low Expression in Primates Highlight Translational Challenges for Liver-directed AAV8-mediated Gene Therapy
200. Evaluation of Systemic Follistatin as an Adjuvant to Stimulate Muscle Repair and Improve Motor Function in Pompe Mice
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.